Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOGIK2102: carboplatin + nab-paclitaxel + atezolizumab for TTF-1-negative advanced non-squamous NSCLC
jRCTs071220008Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of carboplatin, paclitaxel and atezolizumab in Non-small cell lung cancer (NS-NSCLC), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Progression-free survival. Started Jul 2022; status: completed.
02
Drugs
carboplatinpaclitaxelatezolizumab
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on jRCTs071220008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs071220008.